Fish oil Omega-3 market faces "double" threat (II)

Yesterday we talked about clinical research as a major driver of the rapid growth of the
Omega-3
market, which has grown into a mainstream category in the nutritional supplements industry, while the diversity of
Omega-3
sources continues to expand, from marine sources to plants, seeds and others. However, based on changes in the rules of the health industry as a whole, the
Omega-3
market is currently under threat from the
"
double
"
, particularly the
Omega-3
of fish oil sources.In-market growth accelerates Packaging Facts notes that the global
Omega-3
supplement market has stagnated over the past few years, but the
Omega-3
product remains highly popular in the U.S. market, with more companies shifting their focus from the U.S. to the Asia-Pacific market. Market data show that the
market size of Omega-3
end products reached US$
31
.4 billion in

2015. At the same time, growth in Asia was in the two digits, while sales in North America and Europe were essentially flat.data from
Global
EPA
and
DHA Omega-3
(
GOED
) and Packaging Facts show that growth in this category is not very high in the short term.
sales in
2016 amounted to US$
.07 billion
(
-1.3%
) and are expected to be
in
2017.
the

) from 2016 to
reached
1.8%
.
SPINS

data show that fish
oil concentrates were
weeks

52
august
Omega-3
dietary supplements remain mainstream, with a market size of $
302
billion, but down
4.2% from the previous
.other sources
Omega-3
favorite based on marine pollution and widespread antibiotics, purer sources of krill oil
Omega-3
began to become the focus of market attention, the market size of
74.5 million
U.S. dollars, from
2016
market decline
7.4
. At the same time, the
Omega-3
, a market for more plant sources, such as flaxseed source
Omega-3
, has started to attract market attention, with a market size of $
46 million
and a decline of
10.7%
;Chia seed oil market size
7.
5 million U.S. dollars, market decline
16.2%
; black seed oil
Omega-3
Market size
3.
million, market increased
224%
, seaweed source
Omega-3
market size reached
3.
million, Market increased
57.8%
, while sea buckthorn
Omega-3
market size reached
80.78 million U.S. dollars
, down
22.9%
。Figure
1
: Plant Sources
Omega-3
Market Size (US$ 10,000)Threats from Pharmaceutical Companies Omega-3
The market is now under threat from pharmaceutical companies in addition to source challenges in its development. Recently,
Amarin
Pharmaceuticals Effective and
Amarin
Pharmaceutical Ireland Ltd. filed an application with the U.S. International Trade Commission (
ITC
) to investigate synthetics illegally imported and sold in the United States.
Omega-3
products, the
EPA
is mainly in the form of ethyl
EE
) or reesteration (
rTG
). The company said the products constituted false propaganda, incorrectly labeled as dietary supplements, and asked the U.S.
ITC
to issue general discharge orders, limited exclusion orders and prohibition orders.is currently the main force in the U.S.
Omega-3
supplement market, with
ethyl ethyl products accounting for
12% of the U.S. dietary supplement market in .
Amarin
said the survey was not an investigation into dietary supplements for natural fish oil, nor on
Omega-3
products in the form of
EE
or
rTG
, but rather on products with low levels of
EPA
.
CRN
points out that
EPA
in the form of
EE
or
rTG
has a long history of use and is considered a beneficial dietary supplement that helps increase fatty acid levels in the body.
head
CRN said the
Amarin
pharmaceutical company's complaint represented to some extent the pharmaceutical industry's competition for fish oil products. Pharmaceutical companies are spending a lot of resources on
Omega-3
research, and
FDA
has authorized health claims, so it's looking to the more promising dietary supplement market.Amarin
claims that
EPA
products in
or
RTG


are unapproved new drugs.
FDA
whether the product belongs to a drug or a health care product, it measures the use of the product and the final decision depends on
FDA
. in response to
Amarin
's application,
CRN
also filed a document with the International Trade Commission, first prohibiting the sale of
Omega-3
fatty acid products from the public interest, and second, hoping that
ITC
would reject the application. At the same time,
GOED
filed a document with
ITC
indicating that restricting the sale of
EPA
products is in conflict with the Dietary Supplements Health and Education Act of
,
, 1994. Currently,
Omega-3
products are sold through a wide range of channels, such as grocery stores,
24
-hour pharmacies and networks. However, once an application from
Amarin
Pharmaceuticals is approved, the sales channels for such products can only be obtained by doctors, and the appearance of
Omega-3
products in the form of prescription drugs can consume a significant amount of time and resources, increasing the cost of consuming the product.overall,
Omega-3
fatty acid supplements have come under competition from pharmaceutical companies because the sources of supplements and drugs
Omega-3
are the same. Pharmaceutical companies offer higher prices when purchasing, which can have an impact on the supply of raw materials in the dietary supplement industry. At the same time, pharmaceutical companies invest a lot of human and material resources in scientific research and consumer awareness education.